Can you drink alcohol with denosumab?
by Drugs.com While there are no known drug interactions between Prolia (generic name: denosumab) and alcohol, you should check with your doctor first before you combined the two. Some research has shown that drinking alcohol may increase your risk of osteoporosis, a bone fracture or impaired healing after a fracture.
How long does Xgeva stay in your system?
This is when you’ll usually receive the next dose to maintain the drug’s effect. If you don’t receive another dose of Xgeva, the amount of drug in your body will reduce by half after another 4 weeks. This continues until there is no more drug in your body. The drug stays in your body for about 140 days.
Does Xgeva make you tired?
These side effects can vary, depending on the condition the drug is being used to treat. Examples of Xgeva’s commonly reported side effects may include: fatigue (lack of energy) low level of phosphate in your blood.
Does denosumab cause weight gain?
Prolia (denosumab) has not been associated with weight gain in clinical studies. Prolia can cause peripheral edema (fluid retention) or swelling, and this may lead to weight gain in some people. Speak with your doctor if you have any side effect that bothers you or that does not go away.
When should I stop taking Xgeva?
Official Answer. Xgeva is meant to be taken long-term. However, Xgeva should be discontinued if you experience intolerable side effects or serious side effects such as osteonecrosis of the jaw or osteomyelitis, or if Xgeva appears to be ineffective for you.
Does Xgeva cause shortness of breath?
Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: jaw pain, new or unusual thigh/hip/groin pain, bone/joint/muscle pain, shortness of breath.
Does Xgeva strengthen bones?
Xgeva is a brand (trade) name for denosumab which may be used to decrease bone breakdown and increase bone density and strength.
Does Xgeva prevent metastasis?
Xgeva (denosumab) is a preventive medicine developed by Amgen to check the spread of cancer to the bones. It was approved by US Food and Drug Administration (FDA) as the first and only rank ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours in 2010.